schizophrenia

PUTRAJAYA: The Court of Appeal on Tuesday (Sept 24) ordered a man to defend himself on the charge of killing his biological father by hitting him with a stick and...

Sep 24 2024

Uncategorized

New research identifies critical gaps in mental health care for adults with schizophrenia spectrum disorders

by Clinical Editor

No Comments

New research finds that adults with schizophrenia spectrum disorders have high rates of comorbid mental and substance use disorders and significant social and economic disadvantages, and only 26% received minimally...

Sep 23 2024

Uncategorized

Owning a Cat Could Double Your Schizophrenia Risk, Research Suggests

by Clinical Editor

No Comments

Having a cat as a pet could potentially double a person’s risk of schizophrenia-related disorders, according to a recent study. Australian researchers conducted an analysis of 17 studies published …

Sep 23 2024

Uncategorized

Schizophrenia Space Anticipates First-in-Class FDA Approval for BMS’ KarXT

by Clinical Editor

No Comments

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in three decades—and the company also sees potential...

Sep 22 2024

Uncategorized

Updated rationale for the initial antipsychotic selection for patients with schizophrenia – Nature.com

by Clinical Editor

No Comments

Updated rationale for the initial antipsychotic selection for patients with schizophrenia Nature.com

Sep 22 2024

Uncategorized

YOUR HEALTH: Through Darrell’s eyes: Shattering stigma of Schizophrenia – WAFB

by Clinical Editor

No Comments

YOUR HEALTH: Through Darrell’s eyes: Shattering stigma of Schizophrenia WAFB

Sep 21 2024

Uncategorized

Psychedelics and schizophrenia: a double-edged sword – Nature.com

by Clinical Editor

No Comments

Psychedelics and schizophrenia: a double-edged sword Nature.com

Sep 21 2024

Uncategorized

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia – Yahoo Finance

by Clinical Editor

No Comments

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia Yahoo Finance